Sutro Biopharma (NASDAQ:STRO) Price Target Lowered to $30.00 at HC Wainwright
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its price objective cut by analysts at HC Wainwright from $35.00 to $30.00 in a note issued to investors on Wednesday, The Fly reports. HC Wainwright’s target price points to a potential upside of 462.85% from the company’s current price. Several other research firms have also recently weighed […]
Sutro Biopharma Williamj Newell Sutro Biopharma Inc Zacks Investment Research Connective Portfolio Management Panagora Asset Management Inc
Source: etfdailynews.com